Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis

Main Article Content

Jonathan Silverberg
Sebastien Barbarot
Melinda Gooderham
Jan Simon
Eric Simpson
Azra Kurbasic
Christina Olsen
Michael Cork

Keywords

Atopic Dermatitis, Biologic, Tralokinumab, IL-13, Sleep

Abstract

Abstract not available.

References

1. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

2. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

3. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

4. Chang Y, Chiang B. J Allergy Clin Immunol 2018; 142: 1033−1040.

5. Silverberg JI et al. J Invest Dermatol 2015; 135: 56−66.

6. Jeon C et al. Dermatol Ther (Heidelb) 2017;

7: 249−264. 7. Bieber T. Allergy 2020; 75: 54−62.

8. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480−1489.

9. Popovic B et al. J Mol Biol 2017; 429: 208−219.

10. Simpson E et al. Presented at the American Academy of Dermatology Annual Meeting, March 20–24, 2020, Denver, CO, USA. 11. Lei D et al. Ann Allergy Asthma Immunol 2020; 124: 261−266.

Most read articles by the same author(s)

1 2 3 > >>